- "The company has reached the conclusion that, on balance, the benefits of treating patients with fasiglifam do not outweigh the potential risks,” Takeda (TKPHF) says, ending development of its late-stage GPR40 agonist TAK-875.
- The drug was tied to liver damage.
- The company had hoped the treatment would help offset revenue lost to generic Actos, the diabetes drug which at one time accounted for more than a quarter of Takeda's top-line.
- Shares fell 5%+ in Tokyo on the news.
Takeda ends development of late-stage diabetes drug
Dec 27 2013, 07:51 ET